Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecasts
Gilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter.
This figure exceeds analysts' consensus estimate of $221 million, representing an outperformance of roughly $11 million.
The strong performance pushes the company's PrEP franchise past the $1 billion cumulative sales milestone, underscoring the growing demand for long‑acting HIV prevention options.
Gilead noted that the results reflect continued adoption of the twice‑yearly regimen among patients and providers, and the company expects the trend to support future growth.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that